Asset profile
Mepolizumab · Nucala
Monoclonal antibody
Evidence outlook
Approved — Asthma, Chronic Obstructive Pulmonary Disease
Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also in development:Atopic Dermatitis · Phase 2
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.